Hong Kong stocks surged | Qilu Biotechnology-B(02509.HK) rose more than 4% as the dual-target new drug QX027N was authorized to go overseas, with potential payments of up to 700 million US dollars.

According to the Zhitong Finance APP, Qianxin Biological-B (02509.HK) has risen by more than 4%, up 4.36% to 19.61 Hong Kong dollars as of press time, with a turnover of 3.0957 million Hong Kong dollars.